Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.

Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG.

Circulation. 1999 Aug 3;100(5):468-74.

2.
3.

Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121.

Lee LY, Patel SR, Hackett NR, Mack CA, Polce DR, El-Sawy T, Hachamovitch R, Zanzonico P, Sanborn TA, Parikh M, Isom OW, Crystal RG, Rosengart TK.

Ann Thorac Surg. 2000 Jan;69(1):14-23; discussion 23-4.

PMID:
10654479
5.

Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart.

Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK.

J Thorac Cardiovasc Surg. 1998 Jan;115(1):168-76; discussion 176-7.

6.

Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.

Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG.

Mol Ther. 2002 Aug;6(2):287-97.

PMID:
12349828
7.

Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease.

Yang ZJ, Zhang YR, Chen B, Zhang SL, Jia EZ, Wang LS, Zhu TB, Li CJ, Wang H, Huang J, Cao KJ, Ma WZ, Wu B, Wang LS, Wu CT.

Mol Biol Rep. 2009 Jul;36(6):1323-9. doi: 10.1007/s11033-008-9315-3. Epub 2008 Jul 22.

PMID:
18649012
8.

Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.

Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM.

Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7.

PMID:
10509970
9.

Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve.

Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG.

Circulation. 2001 Aug 14;104(7):753-5.

10.

Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM.

Circulation. 1998 Dec 22-29;98(25):2800-4.

11.

Gene therapy for myocardial angiogenesis.

Losordo DW, Vale PR, Isner JM.

Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review.

PMID:
10426872
12.

Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure.

Leotta E, Patejunas G, Murphy G, Szokol J, McGregor L, Carbray J, Hamawy A, Winchester D, Hackett N, Crystal R, Rosengart T.

J Thorac Cardiovasc Surg. 2002 Jun;123(6):1101-13.

13.

Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).

Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A, Vanninen E, Mussalo H, Kauppila E, Simula S, Närvänen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Ylä-Herttuala S.

Circulation. 2003 Jun 3;107(21):2677-83. Epub 2003 May 12.

14.

Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease.

Huwer H, Welter C, Ozbek C, Seifert M, Straub U, Greilach P, Kalweit G, Isringhaus H.

Eur J Cardiothorac Surg. 2001 Dec;20(6):1128-34.

PMID:
11717016
15.

Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.

Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH.

Circulation. 2003 Oct 21;108(16):1933-8. Epub 2003 Sep 22.

16.

[Therapeutic angiogenesis with the use of vascular endothelial growth factor 165 gene in the myocardium of miniature swine].

Zhang DZ, Gai LY, Chen YW, Fan RY, Wen YF, Dong W.

Sheng Li Xue Bao. 2001 Jun;53(3):183-7. Chinese.

17.

Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.

Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS.

Gene Ther. 2006 Nov;13(21):1503-11. Epub 2006 Jun 22.

PMID:
16791287
18.

Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.

Rajagopalan S, Mohler E 3rd, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, Blebea J, Goldman C, Trachtenberg JD, Pressler M, Rasmussen H, Annex BH, Hirsch AT; Regional Angiogenesis With Vascular Endothelial Growth Factor trial.

Am Heart J. 2003 Jun;145(6):1114-8.

PMID:
12796772
19.
20.

Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?

Heilmann CA, Attmann T, von Samson P, Göbel H, Marmé D, Beyersdorf F, Lutter G.

Eur J Cardiothorac Surg. 2003 Jan;23(1):74-80.

PMID:
12493508
Items per page

Supplemental Content

Write to the Help Desk